
Antonio Uccelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3357363/publications.pdf Version: 2024-02-01



#	Article	IF	CITATION
1	Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status. Journal of NeuroImmune Pharmacology, 2022, 17, 195-205.	2.1	10
2	MiRâ€142â€3p regulates synaptopathyâ€driven disease progression in multiple sclerosis. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	13
3	High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Multiple Sclerosis and Related Disorders, 2022, 59, 103535.	0.9	18
4	Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study. CNS Drugs, 2022, 36, 83-96.	2.7	4
5	Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 4352.	1.8	15
6	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine, 2022, 80, 104042.	2.7	54
7	Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study. Journal of		

#	Article	IF	CITATIONS
19	Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. Immunity, 2021, 54, 1543-1560.e6.	6.6	42
20	Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells. Vaccines, 2021, 9, 736.	2.1	1
21	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 2021, 12, 704110.	2.2	22
22	Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2579-2588.	2.1	17
23	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine, 2021, 72, 103581.	2.7	184
24	Mesenchymal stem cells instruct a beneficial phenotype in reactive astrocytes. Clia, 2021, 69, 1204-1215.	2.5	9
25	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurology, The, 2021, 20, 917-929.	4.9	42
26	Ecological impact of isolated cognitive relapses in MS. Multiple Sclerosis Journal, 2020, 26, 114-117.	1.4	15
27	Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	1.4	38
28	Effects of aging on finger movements in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101449.	0.9	3
29	Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients. Multiple Sclerosis and Related Disorders, 2020, 39, 101917.	0.9	13
30	A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. Genes, 2020, 11, 1152.	1.0	5
31	Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study. Journal of Clinical Neuroscience, 2020, 81, 139-143.	0.8	10
32	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically III Mechanically Ventilated COVID-19 Patients. Frontiers in Neurology, 2020, 11, 602114.	1.1	36
33	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. Frontiers in Neuroscience, 2020, 14, 584161.	1.4	12
34	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	30
35	COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. Journal of the Neurological Sciences, 2020, 418, 117114.	0.3	24
36	Effect of vitamin D supplementation on Nâ€glycan branching and cellular immunophenotypes in MS. Annals of Clinical and Translational Neurology, 2020, 7, 1628-1641.	1.7	3

#	Article	IF	CITATIONS
37	Assessing upper limb function in multiple sclerosis using an engineered glove. European Journal of Neurology, 2020, 27, 2561-2567.	1.7	4
38	Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration. Journal of Neuroinflammation, 2020, 17, 228.	3.1	27
39	18F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress. International Journal of Molecular Sciences, 2020, 21, 8154.	1.8	6
40	Aggressive multiple sclerosis: a singleâ€centre, realâ€world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. European Journal of Neurology, 2020, 27, 2047-2055.	1.7	18
41	CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 1450.	1.0	26
42	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	1.4	21
43	Impact of treatment on cellular immunophenotype in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	17
44	Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of "black holes― European Radiology, 2020, 30, 3843-3851.	2.3	4
45	Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population. CNS Drugs, 2020, 34, 425-432.	2.7	25
46	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040.	1.5	28
47	Ghost spasticity in multiple sclerosis. Journal of Electromyography and Kinesiology, 2020, 51, 102408.	0.7	5
48	COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?. Multiple Sclerosis and Related Disorders, 2020, 42, 102120.	0.9	138
49	Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e695.	3.1	8
50	Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. Acta Neuropathologica, 2019, 138, 987-1012.	3.9	120
51	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	4.9	110
52	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 36, 101430.	0.9	23
53	IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism. Cell Death and Disease, 2019, 10, 85.	2.7	34
54	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials, 2019, 20, 263.	0.7	58

#	Article	IF	CITATIONS
55	Could arterial spin labelling perfusion imaging uncover the invisible in <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate receptor encephalitis?. European Journal of Neurology, 2019, 26, e86-e87.	1.7	7
56	Different MRI patterns in MS worsening after stopping fingolimod. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e566.	3.1	18
57	Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. PLoS ONE, 2019, 14, e0213508.	1.1	33
58	Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis. JAMA Neurology, 2019, 76, 866.	4.5	27
59	CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS. Multiple Sclerosis and Related Disorders, 2019, 31, 93-96.	0.9	10
60	Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e596.	3.1	23
61	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	0.9	59
62	Tocilizumab in MOC-antibody spectrum disorder: a case report. Multiple Sclerosis and Related Disorders, 2019, 27, 312-314.	0.9	24
63	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. NeuroImage, 2019, 184, 490-495.	2.1	56
64	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. Frontiers in Neurology, 2019, 10, 1385.	1.1	26
65	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.5	102
66	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.5	74
67	Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. Multiple Sclerosis Journal, 2018, 24, 1133-1137.	1.4	32
68	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
69	Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. Multiple Sclerosis Journal, 2018, 24, 623-631.	1.4	8
70	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	1.4	101
71	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	1.8	43
72	Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2018, 26, 52-54.	0.9	9

#	Article	IF	CITATIONS
73	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Preference and Adherence, 2017, Volume 11, 33-45.	0.8	65
74	Quantitative 3D investigation of Neuronal network in mouse spinal cord model. Scientific Reports, 2017, 7, 41054.	1.6	40
75	Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology, 2017, 88, 2115-2122.	1.5	134
76	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. Immunology Letters, 2017, 181, 109-115.	1.1	16
77	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	1.8	44
78	Teriflunomide treatment reduces B cells in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e403.	3.1	28
79	A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter. Neurological Sciences, 2017, 38, 213-216.	0.9	2
80	X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model. Scientific Reports, 2017, 7, 5890.	1.6	64
81	Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e377.	3.1	46
82	Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration. Metabolism: Clinical and Experimental, 2017, 77, 39-46.	1.5	67
83	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurological Sciences, 2017, 38, 53-59.	0.9	25
84	IFN-Î ³ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. Journal of Allergy and Clinical Immunology, 2017, 139, 1667-1676.	1.5	46
85	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
86	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2016, 7, 606.	2.2	88
87	Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial. Frontiers in Behavioral Neuroscience, 2016, 10, 28.	1.0	15
88	NG2, a common denominator for neuroinflammation, blood–brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation. Acta Neuropathologica, 2016, 132, 23-42.	3.9	25
89	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Translational Medicine, 2016, 5, 1506-1514.	1.6	73
90	Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography. Physica Medica, 2016, 32, 1779-1784.	0.4	15

#	Article	IF	CITATIONS
91	Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis. Journal of Autoimmunity, 2016, 72, 8-18.	3.0	95
92	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. Journal of Neurology, 2016, 263, 1727-1735.	1.8	45
93	Sirt6 regulates dendritic cell differentiation, maturation, and function. Aging, 2016, 8, 34-47.	1.4	28
94	Disease re-activation during pregnancy after natalizumab suspension in patients with multiple sclerosis. Journal of the Neurological Sciences, 2015, 357, e297.	0.3	2
95	Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. Stem Cell Research and Therapy, 2015, 6, 245.	2.4	21
96	The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Annals of the New York Academy of Sciences, 2015, 1351, 114-126.	1.8	164
97	A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study. Frontiers in Neurology, 2015, 5, 278.	1.1	27
98	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
99	Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. Multiple Sclerosis Journal, 2015, 21, 1423-1430.	1.4	45
100	Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 442-447.	1.4	34
101	Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathologica, 2015, 130, 279-295.	3.9	160
102	Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. Immunology Letters, 2015, 168, 183-190.	1.1	59
103	Mesenchymal stromal cells and immunity: Introductory overview. Immunology Letters, 2015, 168, 127-128.	1.1	10
104	Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 622-629.	1.4	36
105	Isolated cognitive relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1035-1037.	0.9	101
106	Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology, 2014, 141, 328-339.	2.0	67
107	Monomethyl fumarate inhibits the NFkB pathway and pro-inflammatory cytokine expression in microglia through HCA2 signaling via the AMPK/Sirt axis. Journal of Neuroimmunology, 2014, 275, 167-168.	1.1	2
108	Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity. Journal of Neuroimmunology, 2014, 275, 54-55.	1.1	0

#	Article	IF	CITATIONS
109	Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma?. Journal of Neuroimmunology, 2014, 275, 218.	1.1	0
110	Bone marrow mesenchymal stem cell-derived secreted factors promote the proliferation of adult subventricular zone-neural stem cells and foster their stemness in vitro under pathogenic conditions. Journal of Neuroimmunology, 2014, 275, 195.	1.1	0
111	Analysis of the interferon gamma modulated pathways related to the therapeutic plasticity of bone marrow-derived mesenchymal stem cells through a SILAC-based proteomic approach. Journal of Neuroimmunology, 2014, 275, 191-192.	1.1	0
112	Lack of NG2 expression on immune cells and oligodendrocytes progenitor cells modulates EAE phenotype. Journal of Neuroimmunology, 2014, 275, 148-149.	1.1	0
113	Possible role of miRNAs in the modulation of neuroinflammation by mesenchymal stem cells. Journal of Neuroimmunology, 2014, 275, 150.	1.1	0
114	Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability. Brain Research, 2014, 1585, 91-98.	1.1	16
115	Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central <scp>CCL</scp> 5 overproduction. British Journal of Pharmacology, 2014, 171, 2457-2467.	2.7	19
116	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. BMC Neurology, 2014, 14, 103.	0.8	10
117	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology, 2014, 14, 65.	0.8	47
118	Mesenchymal stem cells exert a remarkable regenerative effect requiring minimal CNS integration. Experimental Neurology, 2013, 247, 292-295.	2.0	13
119	Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. Journal of NeuroImmune Pharmacology, 2013, 8, 1106-1113.	2.1	69
120	Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. Journal of NeuroImmune Pharmacology, 2013, 8, 944-955.	2.1	29
121	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. Neuropharmacology, 2013, 75, 337-346.	2.0	25
122	Mesenchymal stem cells as treatment for MS – progress to date. Multiple Sclerosis Journal, 2013, 19, 515-519.	1.4	62
123	Towards Clinical Application of Mesenchymal Stem Cells for Treatment of Neurological Diseases of the Central Nervous System. Journal of NeuroImmune Pharmacology, 2013, 8, 1062-1076.	2.1	45
124	Reward responsiveness and fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 233-240.	1.4	41
125	Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Multiple Sclerosis Journal, 2013, 19, 1236-1237.	1.4	30
126	10 Mesenchymal stem cells as a strategy for the treatment of multiple sclerosis and other diseases of the central nervous system. , 2013, , 185-210.		0

ARTICLE IF CITATIONS Quantitative Assessment of Finger Motor Impairment in Multiple Sclerosis. PLoS ONE, 2013, 8, e65225. 1.1 44 Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis., 2013, , 433-455. 128 4 Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, 129 1.0 48 Controversies, Clinical Experience. Current Drug Targets, 2013, 14, 637-643. Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, 130 1.0 0 Controversies, Clinical Experience. Current Drug Targets, 2013, 999, 1-6. Anti–Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia. Archives of Néurology, 2012, 69, 1064-6. Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface 132 0.4 26 Expression of IFN-Î³R2. Journal of Immunology, 2012, 188, 1011-1018. Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune 64 Encephalomyelitis. Journal of Neuropathology and Experimental Neurology, 2012, 71, 840-854. Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function in Experimental 134 1.9 135 Amyotrophic Lateral Śclerosis. Molecular Medicine, 2012, 18, 794-804. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Research and Therapy, 2.4 68 <u>2012, 3, 3.</u> Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of CX3CL1. Stem 136 1.4 127 Cells, 2012, 30, 2044-2053. Patient adherence to and tolerability of self-administered interferon \hat{I}^2 -1a using an electronic 0.8 autoinjection device: a multicentre, open-label, phase IV study. BMC Neurology, 2012, 12, 7. Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk 138 2.1 29 Stratification. Journal of Neurolmmune Pharmacology, 2012, 7, 665-672. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Multiple Sclerosis Journal, 2012, 18, 1.4 835-842. Neurorepair with mesenchymal stem cells: hope or hype?. Lancet Neurology, The, 2012, 11, 123-125. 140 4.9 13 Tâ€cell trafficking in the central nervous system. Immunological Reviews, 2012, 248, 216-227. 2.8 A case of thyroiditis during natalizumab therapy for multiple sclerosis. Journal of Endocrinological 142 1.8 8 Investigation, 2011, 34, 408-409. Regulation of Human Mesenchymal Stem Cell Functions by an Autocrine Loop Involving 1.1 50 NAD⁺Release and P2Y11-Mediated Signaling. Stem Cells and Development, 2011, 20, 1183-1198. Neuroprotective features of mesenchymal stem cells. Best Practice and Research in Clinical 144 0.7 195 Haematology, 2011, 24, 59-64.

#	Article	IF	CITATIONS
145	Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter?. Current Stem Cell Research and Therapy, 2011, 6, 69-72.	0.6	21
146	Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurology, The, 2011, 10, 649-656.	4.9	279
147	Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurological Sciences, 2011, 32, 181-182.	0.9	31
148	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurological Sciences, 2011, 32, 1223-1231.	0.9	43
149	Can we kill an extra bird with the same stone?. Inflammatory Bowel Diseases, 2011, 17, E124-E125.	0.9	1
150	Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17384-17389.	3.3	241
151	Primary varicella zoster infection associated with fingolimod treatment. Neurology, 2011, 76, 1023-1024.	1.5	36
152	Stem cell transplantation in multiple sclerosis. Current Opinion in Neurology, 2010, 23, 218-225.	1.8	50
153	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. Experimental Hematology, 2010, 38, 968-977.	0.2	21
154	Interferonâ€Ĥ3–dependent inhibition of B cell activation by bone marrow–derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 2776-2786.	6.7	161
155	Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?. Current Opinion in Immunology, 2010, 22, 768-774.	2.4	124
156	Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis. Journal of Neurochemistry, 2010, 115, 343-352.	2.1	12
157	Systemic Administration of Mesenchymal Stem Cells Increases Neuron Survival after Global Cerebral Ischemia In Vivo (2VO). Neural Plasticity, 2010, 2010, 1-5.	1.0	24
158	Surrogate endpoints for EDSS worsening in multiple sclerosis. Neurology, 2010, 75, 302-309.	1.5	103
159	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis Journal, 2010, 16, 503-510.	1.4	212
160	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS ONE, 2009, 4, e7897.	1.1	143
161	Immuno-Therapeutic Potential of Haematopoietic and Mesenchymal Stem Cell Transplantation in MS. Results and Problems in Cell Differentiation, 2009, 51, 237-257.	0.2	11
162	Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b. Neurological Sciences, 2009, 30, 21-31.	0.9	32

#	Article	IF	CITATIONS
163	Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks. Neurological Sciences, 2009, 30, 175-177.	0.9	14
164	Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. Eye, 2009, 23, 407-412.	1.1	21
165	Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplantation, 2009, 43, 821-828.	1.3	99
166	C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nature Immunology, 2009, 10, 514-523.	7.0	1,030
167	Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect <i>in vivo</i> . Journal of Neurochemistry, 2009, 110, 1674-1684.	2.1	169
168	Reciprocal Interactions Between Human Mesenchymal Stem Cells and <i>γδ</i> T Cells Or Invariant Natural Killer T Cells. Stem Cells, 2009, 27, 693-702.	1.4	150
169	FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-β. Journal of the Neurological Sciences, 2009, 285, S84.	0.3	0
170	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE Blood, 2009, 114, 4732-4732.	0.6	0
171	Mesenchymal stem cells in health and disease. Nature Reviews Immunology, 2008, 8, 726-736.	10.6	3,028
172	Immunotherapy for neurological diseases. Clinical Immunology, 2008, 128, 294-305.	1.4	51
173	Investigation of paroxysmal dystonia in a patient with multiple sclerosis: A transcranial magnetic stimulation study. Clinical Neurophysiology, 2008, 119, 63-70.	0.7	16
174	Adult stem cells for spinal cord injury: what types and how do they work?. Cytotherapy, 2008, 10, 541-542.	0.3	9
175	Is there a role for mesenchymal stem cells in autoimmune diseases?. Autoimmunity, 2008, 41, 592-595.	1.2	41
176	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	1.4	72
177	Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica, 2008, 93, 339-346.	1.7	159
178	Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Anti–Myelin-Associated Glycoprotein Polyneuropathy. Archives of Neurology, 2007, 64, 1531.	4.9	30
179	Stem cells for multiple sclerosis: promises and reality. Regenerative Medicine, 2007, 2, 7-9.	0.8	7
180	Mesenchymal stem cells: a new strategy for immunosuppression?. Trends in Immunology, 2007, 28, 219-226.	2.9	424

#	Article	IF	CITATIONS
181	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Research and Therapy, 2007, 9, 301.	1.6	150
182	Neuropathological Advances in Multiple Sclerosis. , 2007, , 3-9.		0
183	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Annals of Neurology, 2007, 61, 219-227.	2.8	450
184	The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics, 2007, 8, 65.	1.2	61
185	Antibodies against Epstein–Barr virus and herpesvirus type 6 are associated with the early phases of Multiple Sclerosis. Journal of Neuroimmunology, 2007, 192, 184-185.	1.1	21
186	Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: A 10-Year Experience. Annals of the New York Academy of Sciences, 2007, 1110, 455-464.	1.8	26
187	Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State. Stem Cells, 2007, 25, 1753-1760.	1.4	231
188	Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opinion on Biological Therapy, 2006, 6, 17-22.	1.4	63
189	Human mesenchymal stem cells modulate B-cell functions. Blood, 2006, 107, 367-372.	0.6	1,583
190	Costs and quality of life of multiple sclerosis in Italy. European Journal of Health Economics, 2006, 7, 45-54.	1.4	54
191	OR.82. Mesenchymal Stem Cells Treat CNS Autoimmunity Through a Dual Effect On Inflammation and Tissue Damage. Clinical Immunology, 2006, 119, S35.	1.4	0
192	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. , 2006, 111, 555-566.		30
193	Immunoregulatory function of mesenchymal stem cells. European Journal of Immunology, 2006, 36, 2566-2573.	1.6	490
194	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics, 2006, 15, 2813-2824.	1.4	279
195	Conventional Perimetry, Short-Wavelength Automated Perimetry, Frequency-Doubling Technology, and Visual Evoked Potentials in the Assessment of Patients with Multiple Sclerosis. European Journal of Ophthalmology, 2005, 15, 730-738.	0.7	25
196	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106, 1755-1761.	0.6	1,318
197	B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmunity Reviews, 2005, 4, 549-554.	2.5	54
198	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. Journal of Neuroimmunology, 2005, 165, 192-200.	1.1	38

#	Article	IF	CITATIONS
199	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurological Sciences, 2005, 26, s200-s203.	0.9	17
200	Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 367-371.	1.4	73
201	Unveiling the enigma of the CNS as a B-cell fostering environment. Trends in Immunology, 2005, 26, 254-259.	2.9	87
202	The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921.	1.5	274
203	Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11064-11069.	3.3	322
204	α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2004, 148, 146-153.	1.1	118
205	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Research, 2004, 7, R256.	2.0	56
206	Biological markers of the inflammatory phase of multiple sclerosis. Neurological Sciences, 2003, 24, s271-s274.	0.9	24
207	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. Journal of Leukocyte Biology, 2003, 73, 584-590.	1.5	159
208	Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain, 2003, 126, 285-291.	3.7	109
209	EAE in the common marmoset Callithrix jacchus. International MS Journal, 2003, 10, 6-12.	0.3	13
210	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. Journal of the Neurological Sciences, 2001, 184, 41-49.	0.3	74
211	Central and peripheral nervous system complications following allogeneic bone marrow transplantation. European Journal of Neurology, 2001, 8, 77-80.	1.7	37
212	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. European Journal of Immunology, 2001, 31, 474-479.	1.6	9
213	Delivery to the Central Nervous System of a Nonreplicative Herpes Simplex Type 1 Vector Engineered with the Interleukin 4 Gene Protects Rhesus Monkeys from Hyperacute Autoimmune Encephalomyelitis. Human Gene Therapy, 2001, 12, 905-920.	1.4	57
214	Guillain–Barré Syndrome after Reactivation of Varicella–Zoster Virus. New England Journal of Medicine, 2001, 344, 65-66.	13.9	9
215	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. European Journal of Immunology, 2001, 31, 474-9.	1.6	1
216	Restricted immune responses lead to CNS demyelination and axonal damage. Journal of Neuroimmunology, 2000, 107, 178-183.	1.1	11

#	Article	IF	CITATIONS
217	Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. Journal of Neuroimmunology, 2000, 110, 240-243.	1.1	12
218	Myelin/Oligodendrocyte Glycoprotein-Induced Autoimmune Encephalomyelitis in Common Marmosets: The Encephalitogenic T Cell Epitope pMOG24–36 Is Presented by a Monomorphic MHC Class II Molecule. Journal of Immunology, 2000, 165, 1093-1101.	0.4	123
219	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 192-193.	1.4	49
220	Low-Dose Gabapentin Combined with either Lamotrigine or Carbamazepine Can Be Useful Therapies for Trigeminal Neuralgia in Multiple Sclerosis. European Neurology, 2000, 44, 45-48.	0.6	108
221	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 192-193.	1.4	2
222	A major influence of the T cell receptor repertoire as compared to antigen processing–presentation in the selection of myelin basic protein epitopes in multiple sclerosis. Journal of Neuroimmunology, 1999, 96, 241-244.	1.1	1
223	Multiple sclerosis and non-communicating syringomyelia: a casual association or linked diseases?. Acta Neurologica Scandinavica, 1999, 100, 270-273.	1.0	7
224	Animal Models of Demyelination of the Central Nervous System. , 1999, , 233-245.		2
225	Experimental autoimmune encephalomyelitis in the common marmoset Callithrix jacchus. , 1999, , 79-84.		0
226	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clinical and Experimental Immunology, 1998, 111, 186-192.	1.1	18
227	An open-lebel trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology, 1998, 51, 609-611.	1.5	119
228	Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology, 1998, 50, 1127-1133.	1.5	98
229	Differential display analysis of murine encephalitogenic mRNA International Immunology, 1998, 10, 1819-1823.	1.8	6
230	Characterization of the TCRB chain repertoire in the New World monkey Callithrix jacchus. Journal of Immunology, 1997, 158, 1201-7.	0.4	34
231	Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. Journal of Immunology, 1997, 158, 1428-37.	0.4	70
232	Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3601-3605.	3.3	173
233	17p11.2 Duplication Is a Common Finding in Sporadic Cases of Charcot-Marie-Tooth Type 1. European Neurology, 1994, 34, 135-139.	0.6	15
234	Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. Italian Journal of Neurological Sciences, 1994, 15, 49-53.	0.1	6

#	Article	IF	CITATIONS
235	Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases. Journal of the Neurological Sciences, 1994, 125, 215.	0.3	Ο
236	Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases. Journal of the Neurological Sciences, 1994, 122, 20-27.	0.3	18
237	Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. Journal of the Neurological Sciences, 1993, 119, 91-98.	0.3	17
238	Circulating Lymphocyte Subsets after Total Lymphoid Irradiation in Chronic Progressive Multiple Sclerosis. Annals of the New York Academy of Sciences, 1993, 677, 458-461.	1.8	0
239	Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. Journal of Medical Genetics, 1992, 29, 492-3.	1.5	20
240	Interindividual Variability of Cranioencephalic Relationships as Predicted by CT. Journal of Computer Assisted Tomography, 1991, 15, 647-654.	0.5	0